Consolidated Financial Results for the Three Months of the Fiscal Year Ending May 31,2027 (Japan GAAP)

September 17,2026

Company name: Pharmarise Holdings Corporation
Listed on: Tokyo Stock Exchange, Standard Market
Code number: 2796
URL https://www.pharmarise.com/en/
Representative: Masayuki Akiyama, President and Representative Director
Inquiries: Naonori Teramoto, Senior Managing Director, Executive Officer
Phone: +81-3-3362-7130

Scheduled date to commence dividend payments: —
Preparation of supplementary material on financial results: None
Holding of financial results briefing: Yes (for analysts and institutional investors)

(Amounts of less than one million yen are rounded down.)

1. Consolidated financial results for the three months of the fiscal year ending May 31,2027 (from Jun 1,2026 to August 31,2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
August 31,2026	17,242	2.9	68	(54.8)	79	(31.3)	(36)	—
August 31,2025	16,753	10.0	152	188.5	115	399.1	(18)	—

(Note) Comprehensive income Three months ended August 31,2026: (43)million yen [—%]
Three months ended August 31,2025: (24)million yen [—%]

	Earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
August 31,2026	(3.20)	—
August 31,2025	(1.62)	—

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
August 31,2026	31,221	6,657	20.6
May 31,2026	32,680	6,859	20.3

(Reference) Equity As of August 31,2026: 6,433million yen As of May 31,2026: 6,633million yen

2. Cash dividends

	Dividend per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Annual
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended May 31,2026	–	—	—	14.00	14.00
Fiscal year ending May 31,2027	–				
Fiscal year ending May 31,2027 (forecast)	–	—	—	14.00	14.00

(Note) Revision to the dividend forecast announced most recently: None

3. Consolidated earnings forecasts for the fiscal year ending May 31,2027(from Jun 1,2026 to May 31,2027)

(Percentages represent year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Six months	35,181	4.7	359	(10.0)	276	(16.0)	(44)	—	(3.90)
Full year	70,604	1.6	1,014	3.5	736	2.9	11	(90.0)	0.99

(Note) Revision to the financial results forecast announced most recently: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None
New: — (company name)   Exception: — (company name)

(2) Application of special accounting treatments for preparation of quarterly consolidated financial statements: Yes
Note: For more detail, please see "1. Quarterly Consolidated Financial Statements and Notes, (3) Notes on quarterly consolidated financial statements" on page 6 of the appendices.

(3) Changes in accounting policies, changes in accounting estimates, and restatement
- (i) Changes in accounting policies due to the revision of accounting standards and other: None
- (ii) Changes in accounting policies other than (i): None
- (iii) Changes in accounting estimates: None
- (iv) Retrospective restatement: None

(4) Number of issued shares (common shares)

(i)	Total number of issued shares at the end of the period (including treasury shares):			
	As of August 31,2026	12,060,381shares	As of May 31,2026	12,060,381shares
(ii)	Total number of treasury shares at the end of the period:			
	As of August 31,2026	557,856shares	As of May 31,2026	557,856shares
(iii)	Average number of shares issued and outstanding in each period (cumulative from the beginning of the fiscal year):			
	Three months ended August 31,2026	11,502,525shares	Three months ended August 31,2025	11,360,905shares

* Review by certified public accountants or audit firms of the attached quarterly consolidated financial statements: None

* Proper use of earnings forecasts, and other special matters

The forward-looking statements such as the forecasts of financial results stated in this document are based on the information currently available to the Company and certain assumptions that the Company judges as rational. These statements are not guarantees of future performance. Actual results may differ materially, depending on a range of factors.

Table of contents for Appendices

1. Quarterly Consolidated Financial Statements and Notes 2
(1) Quarterly consolidated balance sheet 2
(2) Quarterly consolidated statements of income and comprehensive income 4
(3) Notes on quarterly consolidated financial statements 6
(Note on going concern assumption) 6
(Note on significant changes in shareholders' equity) 6
(Application of special accounting treatments for preparation of quarterly consolidated financial statements) 6
(Segment information and related items) 7
(Note on statement of cash flows) 7

1. Quarterly Consolidated Financial Statements and Notes

(1) Quarterly consolidated balance sheet

(Million yen)

	As of May 31,2026	As of August 31,2026
Assets		
Current assets		
Cash and deposits	6,012	2,941
Accounts receivable - trade	1,120	1,339
Merchandise and finished goods	2,713	3,637
Raw materials and supplies	99	89
Accounts receivable - other	2,638	3,111
Other	596	881
Allowance for doubtful accounts	(17)	(15)
Total current assets	13,164	11,985
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	3,525	3,623
Land	3,227	3,247
Other, net	868	806
Total property, plant and equipment	7,621	7,677
Intangible assets		
Goodwill	7,257	7,044
Other	345	313
Total intangible assets	7,602	7,357
Investments and other assets		
Other	4,380	4,288
Allowance for doubtful accounts	(87)	(87)
Total investments and other assets	4,292	4,200
Total non-current assets	19,516	19,235
Total assets	32,680	31,221

(Million yen)

	As of May 31,2026	As of August 31,2026
Liabilities		
Current liabilities		
Accounts payable - trade	6,627	7,015
Current portion of long-term borrowings	4,781	4,663
Income taxes payable	347	114
Provision for bonuses	8	324
Other	2,246	1,271
Total current liabilities	14,010	13,389
Non-current liabilities		
Long-term borrowings	9,810	9,167
Retirement benefit liability	1,054	1,070
Asset retirement obligations	246	244
Other	698	690
Total non-current liabilities	11,810	11,173
Total liabilities	25,820	24,563
Net assets		
Shareholders’ equity		
Share capital	1,961	1,961
Capital surplus	2,091	2,091
Retained earnings	2,893	2,697
Treasury shares	(376)	(376)
Total shareholders’ equity	6,570	6,374
Accumulated other comprehensive income		
Remeasurements of defined benefit plans	63	59
Total accumulated other comprehensive income	63	59
Share acquisition rights	208	208
Non-controlling interests	17	15
Total net assets	6,859	6,657
Total liabilities and net assets	32,680	31,221

(2) Quarterly consolidated statements of income and comprehensive income

Quarterly consolidated statement of income

For the Three-Month period

(Million yen)

	Three months ended August 31,2025	Three months ended August 31,2026
Net sales	16,753	17,242
Cost of sales	14,520	15,008
Gross profit	2,232	2,234
Selling, general and administrative expenses	2,080	2,165
Operating profit	152	68
Non-operating income		
Interest income	3	6
Dividend income	0	0
Rental income	13	11
Gain on insurance cancellation	—	92
Other	12	15
Total non-operating income	29	125
Non-operating expenses		
Interest expenses	61	95
Cost of lease revenue	3	7
Other	1	11
Total non-operating expenses	65	115
Ordinary profit	115	79
Extraordinary income		
Gain on sale of non-current assets	15	0
Subsidy income	3	11
Total extraordinary income	18	12
Extraordinary losses		
Loss on sale of non-current assets	—	1
Loss on retirement of non-current assets	0	0
Loss on tax purpose reduction entry of non-current assets	2	11
Total extraordinary losses	2	12
Profit before income taxes	131	78
Income taxes	153	117
Profit (loss)	(22)	(38)
Profit (loss) attributable to non-controlling interests	(3)	(1)
Profit (loss) attributable to owners of parent	(18)	(36)

Quarterly consolidated statement of comprehensive income

For the Three- Month period

(Million yen)

	Three months ended August 31,2025	Three months ended August 31,2026
Profit (loss)	(22)	(38)
Other comprehensive income		
Remeasurements of defined benefit plans, net of tax	(2)	(4)
Total other comprehensive income	(2)	(4)
Comprehensive income	(24)	(43)
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	(28)	(41)
Comprehensive income attributable to non-controlling interests	3	(1)

(3) Notes on quarterly consolidated financial statements

(Note on going concern assumption)

Not applicable.

(Note on significant changes in the amount of shareholders' equity)

Not applicable.

(Application of special accounting treatments for preparation of quarterly consolidated financial statements)

(Calculation of income taxes)

Income taxes are calculated by applying a reasonably estimated effective tax rate, after tax-effect accounting, to profit before income taxes for the quarter. The effective tax rate is estimated based on profit before income taxes for the current consolidated fiscal year. However, if the application of such estimated effective tax rate results in a significantly unreasonable amount of income taxes, the statutory effective tax rate is used instead.

(Segment information and related items)

(Segment information)

Three months ended August 31,2025

1. Reportable segment sales, profit or loss

(Million yen)

	Reportable segments					Other (Note 1)	Total	Adjustments (Note 2)	Amount in quarterly consolidated statement of income (Note 3)
	Dispensing Pharmacy	Drug/ Convenience Store	Storage and Management of Medical Documents	Medical Mall Management	Total				
Net sales									
Sales to external customers	14,151	2,079	157	128	16,517	235	16,753	—	16,753
Inter-segment net sales or transfers									
Total	14,151	2,079	157	128	16,517	235	16,753	—	16,753
Segment profit (loss)	235	(4)	15	23	270	(35)	234	(82)	152

(Notes) 1. The "other" segment includes the temporary help business and the system integration business for pharmaceutical companies.

2. The adjustment to segment profit (loss) of (82) million yen is company expenses not distributed to the reportable segments.

3. Segment profit (loss) is adjusted to be consistent with the operating profit reported in the consolidated statement of income.

2. Information on impairment loss in non-current assets and goodwill by reportable segment

Not applicable.

Three months ended August 31,2026

1. Reportable segment sales, profit or loss

(Million yen)

	Reportable segments					Other (Note 1)	Total	Adjustments (Note 2)	Amount in quarterly consolidated statement of income (Note 3)
	Dispensing Pharmacy	Drug/ Convenience Store	Storage and Management of Medical Documents	Medical Mall Management	Total				
Net sales									
Sales to external customers	14,474	2,060	138	123	16,796	445	17,242	—	17,242
Inter-segment net sales or transfers									
Total	14,474	2,060	138	123	16,796	445	17,242	—	17,242
Segment profit (loss)	158	(33)	4	18	148	5	153	(84)	68

(Notes) 1. The "other" segment includes the temporary help business and the system integration business for pharmaceutical companies.

2. The adjustment to segment profit (loss) of (84) million yen is company expenses not distributed to the reportable segments.

3. Segment profit (loss) is adjusted to be consistent with the operating profit reported in the consolidated statement of income.

2. Information on impairment loss in non-current assets and goodwill by reportable segment

Not applicable.

(Note on statement of cash flows)

The quarterly consolidated statement of cash flows for the three months of the fiscal year under review is not prepared.

Depreciation (including amortization of intangible assets, excluding amortization of goodwill) and amortization of goodwill for the three months of the consolidated fiscal year under review are as follows.

	Three months ended August 31,2025	Three months ended August 31,2026
Depreciation	181million yen	184million yen
Amortization of goodwill	195million yen	213million yen